Multiple Sclerosis

3 articles published between April 24, 2026 and October 26, 2026.

Covered in Body and Policy.

WHAT THE STUDY ACTUALLY SAYS

Remibrutinib beat an older oral drug on relapses in multiple sclerosis

Two identical phase 3 trials found the BTK inhibitor lowered the annual relapse rate versus teriflunomide — a real win on one endpoint, against a modest comparator, with disability data still to come.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Off-label rituximab matched ocrelizumab in newly diagnosed MS trial

In the head-to-head OVERLORD-MS trial, 92.2% on rituximab and 94.8% on ocrelizumab had no new MRI lesions from months 6 to 24, meeting the prespecified bar for noninferiority.

4 min read

THE DRUG DOCKET

EU regulators back the first drug shown to slow disability in progressive MS

The CHMP backed tolebrutinib for non-relapsing secondary progressive multiple sclerosis, a population with no prior disability-targeting treatment. The trial showed a 31% delay in progression.

3 min read

This page indexes this newspaper’s reporting on Multiple Sclerosis. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.